Celltrion Pharm

The company's flagship chemical drug for liver disease; it ranked first in Korean liver-drug prescriptions in 2025, with sales of 17.7 billion won in Q2 2026.

Supplies Celltrion group biologics in Korea, including Remsima, Remsima SC, Truxima, Herzuma and Omlyclo; biosimilar segment revenue was 36.6 billion won in Q2 2026.

Head office and plant in Ochang-eup, Cheongwon-gu, Cheongju, North Chungcheong; the first Korean oral solid dose facility approved under GMP by both U.S. and European regulators. It produces tablets and capsules at roughly 5 billion units a year, and its PFS line received approvals from the U.S. FDA, Japan's PMDA and others in 2023.

Offers tailored contract manufacturing from formulation development to finished product, covering oral solid doses and PFS drug products; Q2 2026 CMO revenue rose 53.4% year on year to 49.7 billion won on wider PFS demand.

Researches antibody-drug conjugates (ADC), improved and combination drugs, and drug delivery (DDS) technology based on nanoparticles and microspheres; presented ADC dual-payload research at AACR in April 2026.

Launched a 300 mg prefilled syringe form of Omlyclo, an omalizumab biosimilar, in Korea.

Presented antibody-drug conjugate dual-payload research findings at AACR 2026.

Launched a 150 mg auto-injector (AI) form of Omlyclo in Korea, adding a device option to the existing prefilled syringes.

Reported record quarterly results for Q2 2026: revenue of 153.3 billion won and operating profit of 19.3 billion won, with 67.0 billion won from chemical drugs, 36.6 billion won from biosimilars and 49.7 billion won from CMO.